Last reviewed · How we verify
Membrane Bound Cytokine Modified TIL — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Membrane Bound Cytokine Modified TIL (Membrane Bound Cytokine Modified TIL) — Shanghai Juncell Therapeutics.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Membrane Bound Cytokine Modified TIL TARGET | Membrane Bound Cytokine Modified TIL | Shanghai Juncell Therapeutics | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Membrane Bound Cytokine Modified TIL CI watch — RSS
- Membrane Bound Cytokine Modified TIL CI watch — Atom
- Membrane Bound Cytokine Modified TIL CI watch — JSON
- Membrane Bound Cytokine Modified TIL alone — RSS
Cite this brief
Drug Landscape (2026). Membrane Bound Cytokine Modified TIL — Competitive Intelligence Brief. https://druglandscape.com/ci/membrane-bound-cytokine-modified-til. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab